Biotech

3D rendering of SARS-CoV-2 virus particles

Invivyd says Pemgarda sequel could be alternative to COVID shots

Invivyd has touted its follow-up to the FDA-authorized monoclonal antibody Pemgarda as potentially offering better protection than available vaccines.

James Waldron Jun 26, 2025 10:12am

Alto’s phase 2 depression trial misses primary efficacy endpoint

Jun 26, 2025 9:28am

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm

Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug

Jun 26, 2025 8:41am

Guidehouse’s Karla Anderson shares top tips for successful biotech commercialization

Oct 28, 2024 8:00am

red heart wrapped in stethoscope over EKG

Novartis pens ProFound pact for cardiovascular disease targets

Jun 26, 2025 6:30am